Vaxcyte, Inc.
PCVX
Pozycja w akcjach
#2041
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage,... Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease and pneumonia. Beyond its flagship candidate, Vaxcyte is also advancing several other vaccine programs: VAX-XP, designed to offer protection against emergent bacterial strains and counter antimicrobial resistance; VAX-A1, a conjugate vaccine formulation aimed at Group A Streptococcus; and VAX-PG, a novel protein vaccine specifically developed to target the key pathogen responsible for periodontitis. The organization, which was initially established as SutroVax, Inc., officially rebranded as Vaxcyte, Inc. in May 2020. Founded in 2013, its corporate headquarters are situated in San Carlos, California.
Cena akcji
$65.09
Kapitalizacja rynkowa
$9.98B
Zmiana (1 dzień)
-1.73%
Zmiana (1 rok)
53.68%
Kraj
US
Handel Vaxcyte, Inc. (PCVX)
Kategoria
Healthcare
Historia ceny akcji dla Vaxcyte, Inc. (PCVX)
Najwyższa cena zamknięcia: $65.62 dnia 2026-10-01
Najniższa cena zamknięcia: $32.16 dnia 2020-06-01
Najniższa cena zamknięcia: $32.16 dnia 2020-06-01
Historia cen akcji firmy Vaxcyte, Inc. od 2020 do 2026
Roczna wydajność ceny akcji
| Rok | Wydajność |
|---|---|
| 2026 (TTM) | 18.84% |
| 2025 | -48.18% |
| 2024 | 49.19% |
| 2023 | 30.50% |
| 2022 | 103.95% |
| 2021 | -26.14% |
| 2020 | 0.00% |
Cena akcji podobnych firm lub konkurencji
| Firma | Cena akcji | Zmiana 1r% | Kraj |
|---|---|---|---|
| $518.13 | 21.55% |
US
|
|
| $245.75 | 793.96% |
US
|
|
| $138.33 | -3.31% |
AU
|
|
| $881.97 | 5.66% |
NL
|
|
| $752.87 | 7.40% |
CH
|
